Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to Ultragenyx First Quarter 2026 Financial Results Conference Call.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 4,578,024 | $95,909,604 | +237% | 0.04% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 2,205,820 | $46,211,929 | +359% | 0.04% |
| 3. | Citadel Investment Group Ken Griffin | 2,115,491 | $44,319,536 | -10% | 0.01% |
| 4. | Millennium Management Israel Englander | 1,772,184 | $37,127,255 | +102% | 0.02% |
| 5. | D E Shaw D. E. Shaw | 1,261,018 | $26,418,327 | +266% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | $218,150.00 | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | $87,225.12 | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | $306,697.20 | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | $3,675,000.00 | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | $94,500.00 | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.12 | 5,740 | $144,188.80 | 27,951 | 2026-05-18 | Filing | |
| $24.96 | 344 | $8,586.24 | 111,189 | 2026-05-05 | Filing | |
| $24.90 | 4,683 | $116,606.70 | 110,342 | 2026-05-01 | Filing | |
| $20.97 | 4,683 | $98,202.51 | 80,351 | 2026-04-01 | Filing | |
| $22.80 | 10,029 | $228,661.20 | 110,026 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,299,598 | $152,926,579 | 0% | |
| 2. | 5,385,992 | $112,836,532 | 0% | |
| 3. | 5,021,441 | $105,199,189 | 0% | |
| 4. | 4,189,831 | $87,776,959 | 0% | |
| 5. | 3,648,795 | $76,442,255 | 0.76% |
News See All
10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
10 Overlooked Growth Stocks to Buy Now
On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
7 Best Small-Cap Healthcare Stocks to Buy According to Hedge Funds
In this article, we will look at the best small-cap healthcare stocks to buy according to hedge funds.
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE.
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)
On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, who maintained a Buy rating on the stock.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript February 12, 2026Ultragenyx Pharmaceutical Inc. misses on earnings expectations.
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising low-cost stocks to buy now.
11 Most Promising Low-Cost Stocks to Buy Now
On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the state of equity markets, assessing which stocks are growing fast and trading cheaply.
Hedge Fund Resource Center